Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Anti-seizure drugs could cause canine obesity, study finds
Dogs receiving ASD medication had a higher interest in food than healthy dogs.
Dogs taking the medication are more likely to have increased appetite.

New research has revealed that anti-seizure drugs (ASD) could be leading to more epileptic dogs becoming obese.

Researchers say that the drugs cause epileptic dogs to have an increased appetite which, when not properly managed, can cause weight issues. This risk is increased when dogs are given treats to help administer medication.

Dogs which suffer from idiopathic epilepsy are often prescribed ASD throughout their lifetimes. These drugs reduce the frequency and severity of the dog’s seizures, but rarely lead to seizure freedom.

The medication has a number of long-lasting side effects, including decreased energy, increased food intake and weight gain.

Though these side effects are widely published in veterinary literature, they have not previously been quantified or studied.

To analyse food motivation, researchers from the Royal Veterinary College (RVC) collaborated with the University of Cambridge to issue a validated Dog Obesity Risk Assessment questionnaire. The survey was designed to determine the link between ASDs and weight gain, as well as considering how caregivers manage weight gain.

The data compared 222 dogs that were diagnosed with idiopathic epilepsy with a control population of 7,086 healthy dogs.

Dogs which had idiopathic epilepsy and were receiving ASD were found to have a much higher food motivation than healthy dogs. They had increased interest in food, were less selective and were more interested in getting more food outside of meals.

Although their carers put effort into managing their pet’s diet, these dogs still had greater fat mass.

Fifty-three per cent of owners of dogs with epilepsy said they would always use treats to administer ASD medication, with 34 per cent saying they did not adjust their dog’s main food ration to suit. Since medication is usually administered twice a day, this can have a significant increase on calorie intake.

Rowena Packer, principal investigator of this research, said: “The findings of this research are key in helping the veterinary team provide greater information and support to pet owners managing their dog’s epilepsy.

“Although anti-seizure drugs are an essential part of the epilepsy treatment toolkit, ensuring owners are aware of the side effects and long-lasting impact of these medications is key in treatment decision-making, ensuring a balance between negative side effects such as increased food motivation against potential positive effects such as reduced seizure frequency, to maintain quality of life.”

The full study can be found in the journal Vet Record.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.